Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Medical Oncology
Are there any trials looking at alternative treatments for patients who otherwise would receive 2 years of ADT but have the HSD3B1 gene (homozygous vs heterozygous)?
Related Questions
How do you manage drug-drug interactions between oral anticoagulants and the ARSI agents such as apalutamide and enzalutamide?
How would you sequence PARPi vs pembrolizumab for a patient who has progressed on ARPI to mCRPC that has somatic PALB2 mutation and MSI-H?
Would you offer adjuvant immunotherapy (pembrolizumab) for chromophobe RCC with R1 resection?
Would you consider enfortumab vedotin + pembrolizumab prior to surgery for a patient with urothelial carcinoma with regional nodes who is not eligible for neoadjuvant cisplatin?
What is your approach to muscle-invasive bladder cancer in a patient who is ineligible for surgery and radiotherapy?
What perioperative systemic therapy would you use for a patient with oligometastatic clear cell RCC with a bony metastasis at risk for fracture?
Are patients with MIBC and bladder neck involvement good candidates for bladder preservation with chemoradiation after maximal, but not complete, TURBT?
Are there any scenarios in which you would consider use of PARPi in the upfront mCSPC setting rather than reserving for CRPC?
How would you approach the use of bevacizumab in metastatic FH-deficient RCC/HLRCC that is c/b extensive IVC tumor thrombus and DVT/PE?
How do you treat metastatic large cell neuroendocrine carcinoma of prostate with undetectable PSA, who had the treatment related transformation while on ADT monotherapy?
